Press Releases May 7, 2026 07:30 AM

Harvard Bioscience to Participate in Upcoming Investor Conferences

Harvard Bioscience announces CEO and CFO participation in upcoming virtual investor conferences

By Sofia Navarro
Share
Twitter Reddit Facebook LinkedIn
HBIO

Harvard Bioscience, Inc., a developer and manufacturer of life science technologies, announced that its CEO John Duke and CFO Mark Frost will participate in two upcoming virtual investor conferences in May 2026, including the Sidoti Micro Cap Conference and the Benchmark Healthcare House Call Virtual Conference. The company will provide a live webcast and archived replay of the Sidoti event on its investor relations website.

Harvard Bioscience to Participate in Upcoming Investor Conferences
HBIO
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Harvard Bioscience executives to present at Sidoti Micro Cap and Benchmark Healthcare virtual investor conferences.
  • The company operates internationally with a focus on life science technologies aiding pharmaceutical and therapy development.
  • Live webcast and replay of presentations will be made available to investors online.

HOLLISTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced Chief Executive Officer, John Duke and Chief Financial Officer, Mark Frost’s participation in the following upcoming investor events.

Sidoti Micro Cap Conference
Location: Virtual
Date: Thursday, May 21, 2026
Fireside Chat Presentation: 11:30 AM ET

Benchmark (StoneX) Healthcare House Call Virtual Conference
Location: Virtual
Date: Thursday, May 28, 2026

A live webcast of the Sidoti fireside chat will be made available on Harvard Bioscience’s Investor Relations website. An archived replay of the webcast will be available following the event.

About Harvard Bioscience 

Harvard Bioscience, Inc. is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, pharmaceutical and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. Our customers range from renowned academic institutions and government laboratories to the world’s leading pharmaceutical, biotechnology and contract research organizations. With operations in the United States, Europe, and China, we sell through a combination of direct and distribution channels to customers around the world.

For more information, please visit our website at www.harvardbioscience.com.

Company Contact:
Mark Frost
Chief Financial Officer
(508) 893-3120
investors@harvardbioscience.com


Risks

  • Market reception to conference presentations and new information could remain unchanged, limiting stock movement.
  • Broader biotech and healthcare funding environment could affect investor interest and company valuation.
  • Competition and regulatory challenges inherent in biotech product development may limit growth potential.

More from Press Releases

Oral Infigratinib Shows Meaningful Benefits Beyond Growth Within 52 Weeks in Children with Achondroplasia in the Phase 3 PROPEL 3 Trial Sep 9, 2026 Premium Catering (Holdings) Limited Receives NASDAQ Notice Related to Late Filing of Its Interim Report Sep 9, 2026 Zscaler launches Agentic SOC to contain AI-Driven Threats Sep 9, 2026 Launch of StoneX Trading marks a new era for City Index Sep 9, 2026 MulticoreWare and Micware Sign MOU to Explore Potential Collaboration in ADAS Performance Optimization and Physical AI at the Edge Sep 9, 2026